ReviewDeutsches Arzteblatt international2014
Effects and risks associated with novel psychoactive substances: mislabeling and sale as bath salts, spice, and research chemicals.
Review in Deutsches Arzteblatt international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.
- Synthetic Cathinones and Neurotoxicity Risks: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Trial
- 4-Bromomethcathinone (4-BMC) Revisited: The First Reported Fatal Case and Toxicological Insights.Metabolites · 2026Article
- The MDPV Derivative α-PHP Regulates Cellular Differentiation and Triggers Apoptotic Cell Death and Ultrastructural Changes in Murine 3D Neurospheres.Molecules (Basel, Switzerland) · 2026Article
- Perceived HIV knowledge in the context of novel psychoactive substance use: evidence from a multi-city survey in Kazakhstan.Frontiers in public health · 2026Article
- Clinical Management of Synthetic-Cannabinoid-Induced Psychosis: A Systematic Review of Treatment Strategies and Outcomes.Brain sciences · 2025Review
- Synthesis, Characterization, and Biological Effects of Chloro-Cathinones: Toxicity and Potential Neurological Impact.International journal of molecular sciences · 2025Article
- The usefulness of infrared spectroscopy and X-ray powder diffraction in the analysis of falsified, illegal, and medicinal products.Frontiers in chemistry · 2025Review
- Abuse of Synthetic Cannabinoids and Cathinones in a Patient on Buprenorphine-Naloxone Treatment: A Case Report.Cureus · 2023Article
- The Designer Drug αPHP Affected Cell Proliferation and Triggered Deathly Mechanisms in Murine Neural Stem/Progenitor Cells.Biology · 2023Article
- Article
- In Vitro Metabolic Study of Four Synthetic Cathinones: 4-MPD, 2-NMC, 4F-PHP and bk-EPDP.Metabolites · 2022Article
- Pharmacology and adverse effects of new psychoactive substances: synthetic cannabinoid receptor agonists.Archives of pharmacal research · 2021Review
- ["Legal highs" (new psychoactive substances) : What does the anesthesiologist need to know?]Der Anaesthesist · 2020Review
- Designers Drugs-A New Challenge to Emergency Departments-An Observational Study in Poland.Medicina (Kaunas, Lithuania) · 2020Observational
- Extended Stability Evaluation of Selected Cathinones.Frontiers in chemistry · 2020Article
- Assessment of rimonabant-like adverse effects of purported CB1R neutral antagonist / CB2R agonist aminoalkylindole derivatives in mice.Drug and alcohol dependence · 2018Article
- Polysubstance use profiles among electronic dance music party attendees in New York City and their relation to use of new psychoactive substances.Addictive behaviors · 2018Article
- The Consumption of New Psychoactive Substances and Methamphetamine.Deutsches Arzteblatt international · 2018Article
- A synthetic cannabinoid JWH-210 reduces lymphoid organ weights and T-cell activator levels in mice via CBNaunyn-Schmiedeberg's archives of pharmacology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe number of newly reported psychoactive substances in Europe is now higher than ever. In order to evade legal restrictions, old and novel psychoactive substances from medical research and their derivatives are commonly mislabeled as "not for human consumption" and offered for sale on the Internet and elsewhere. Such substances are widely taken by young people as "club drugs." Their consumption must be considered in the differential diagnosis of psychiatric, neurological, cardiovascular, or metabolic disturbances of unclear origin in a young patient.
methodSelective review of pertinent literature retrieved by a PubMed search, including publications by government-sponsored organizations.
resultsFrom 2010 to 2012, 163 substances were reported to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), mostly either synthetic cannabinoids (39.3%) or synthetic cathinones (16.6%). Synthetic cannabinoids alter mood and perception; intoxications cause agitation, tachy cardia, and arterial hypertension. Synthetic cathinones are hallucinogenic stimulants with predominantly cardiovascular and psychiatric side effects. Severe intoxications cause serotonin syndrome and potentially fatal rhabdomyolysis. Substances in either of these classes often escape detection in screening tests.
conclusionYoung persons who present with agitation and cardiovascular and/or psychiatric manifestations of unclear origin and whose drug screening tests are negative may be suffering from an intoxication with a novel psychoactive substance. Physicians should know the classes of such substances and their effects. Targeted toxicological analysis can be carried out in a toxicology laboratory or a facility for forensic medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.